Anika Therapeutics Company Profile (NASDAQ:ANIK)

About Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics logoAnika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company's therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company's ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: Health Care Supplies
  • Symbol: NASDAQ:ANIK
  • CUSIP: 03525510
  • Web: www.anikatherapeutics.com
Capitalization:
  • Market Cap: $876.7 million
  • Outstanding Shares: 14,658,000
Average Prices:
  • 50 Day Moving Avg: $57.54
  • 200 Day Moving Avg: $50.30
  • 52 Week Range: $41.38 - $60.27
P/E:
  • Trailing P/E Ratio: 26.57
  • Foreward P/E Ratio: 35.39
  • P/E Growth: 2.72
Sales & Book Value:
  • Annual Revenue: $111.36 million
  • Price / Sales: 7.87
  • Book Value: $16.66 per share
  • Price / Book: 3.59
Profitability:
  • EBITDA: $56.02 million
  • Net Margins: 30.44%
  • Return on Equity: 14.88%
  • Return on Assets: 13.78%
Debt:
  • Current Ratio: 14.35%
  • Quick Ratio: 13.04%
Misc:
  • Average Volume: 89,612 shs.
  • Beta: 1.66
  • Short Ratio: 14.7
 

Frequently Asked Questions for Anika Therapeutics (NASDAQ:ANIK)

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics Inc. (NASDAQ:ANIK) announced its quarterly earnings data on Wednesday, July, 26th. The company reported $0.76 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.44 by $0.32. The business had revenue of $33.50 million for the quarter, compared to analyst estimates of $27.20 million. Anika Therapeutics had a net margin of 30.44% and a return on equity of 14.88%. The company's revenue was up 25.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.57 EPS. View Anika Therapeutics' Earnings History.

When will Anika Therapeutics make its next earnings announcement?

Anika Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Anika Therapeutics.

Who are some of Anika Therapeutics' key competitors?

Who are Anika Therapeutics' key executives?

Anika Therapeutics' management team includes the folowing people:

  • Joseph G. Darling, President
  • Charles H. Sherwood Ph.D., Chief Executive Officer, Director
  • Sylvia Cheung, Chief Financial Officer, Treasurer, Secretary
  • Dana M. Alexander, Chief Operating Officer
  • Edward Ahn Ph.D., Chief Technology and Strategy Officer
  • Richard Hague, Chief Commercial Officer
  • Joseph Lyon Bower Ph.D., Lead Independent Director
  • Raymond J. Land, Independent Director
  • Glenn R. Larsen Ph.D., Independent Director
  • Jeffrey S. Thompson, Independent Director

Who owns Anika Therapeutics stock?

Anika Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC (11.49%), Fisher Asset Management LLC (0.72%) and Eqis Capital Management Inc. (0.28%). Company insiders that own Anika Therapeutics stock include Charles H Sherwood, Jeffery S Thompson, Joseph I Bower and Raymond J Land. View Institutional Ownership Trends for Anika Therapeutics.

Who bought Anika Therapeutics stock? Who is buying Anika Therapeutics stock?

Anika Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC and Eqis Capital Management Inc.. View Insider Buying and Selling for Anika Therapeutics.

How do I buy Anika Therapeutics stock?

Shares of Anika Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anika Therapeutics' stock price today?

One share of Anika Therapeutics stock can currently be purchased for approximately $59.81.


MarketBeat Community Rating for Anika Therapeutics (NASDAQ ANIK)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  89 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  152
MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Anika Therapeutics (NASDAQ:ANIK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Anika Therapeutics (NASDAQ:ANIK)
Price Target History for Anika Therapeutics (NASDAQ:ANIK)
Analysts' Ratings History for Anika Therapeutics (NASDAQ:ANIK)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/27/2016Northland SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
2/26/2016Barrington ResearchBoost Price TargetOutperform$45.00 -> $49.00N/AView Rating Details
(Data available from 10/23/2015 forward)

Earnings

Earnings History for Anika Therapeutics (NASDAQ:ANIK)
Earnings by Quarter for Anika Therapeutics (NASDAQ:ANIK)
Earnings History by Quarter for Anika Therapeutics (NASDAQ ANIK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017$0.44N/AView Earnings Details
7/26/2017Q2 2017$0.44$0.76$27.20 million$33.50 millionViewN/AView Earnings Details
5/3/2017Q1 2017$0.38$0.37$23.89 million$23.39 millionViewListenView Earnings Details
2/15/2017Q416$0.53$0.54$27.84 million$28.70 millionViewN/AView Earnings Details
10/26/2016Q316$0.47$0.59$26.60 million$25.79 millionViewListenView Earnings Details
7/27/2016Q216$0.44$0.57$24.75 million$26.60 millionViewListenView Earnings Details
4/27/2016Q116$0.28$0.45$19.26 million$22.30 millionViewListenView Earnings Details
2/24/2016Q415$0.60$0.72$28.19 million$25.60 millionViewListenView Earnings Details
10/28/2015Q315$0.34$0.55$22.36 million$23.70 millionViewListenView Earnings Details
7/29/2015Q215$0.34$0.51$21.65 million$22.90 millionViewListenView Earnings Details
4/28/2015Q115$0.21$0.23$16.20 million$15.50 millionViewListenView Earnings Details
2/25/2015Q414$0.48$0.51$24.60 million$23.30 millionViewListenView Earnings Details
10/29/2014Q314$0.33$0.40$20.33 million$22.10 millionViewListenView Earnings Details
7/30/2014Q214$0.57$0.60$28.20 million$26.27 millionViewListenView Earnings Details
4/29/2014Q114$0.25$0.97$16.03 million$34.00 millionViewN/AView Earnings Details
2/26/2014Q413$0.42$0.44$21.91 million$21.30 millionViewListenView Earnings Details
10/31/2013Q313$0.14$0.33$16.96 million$17.80 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.25$0.40$17.09 million$20.80 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Anika Therapeutics (NASDAQ:ANIK)
2017 EPS Consensus Estimate: $1.85
2018 EPS Consensus Estimate: $1.75
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.34$0.42$0.38
Q2 20172$0.42$0.47$0.45
Q3 20172$0.39$0.42$0.41
Q4 20172$0.62$0.62$0.62
Q1 20182$0.32$0.36$0.34
Q2 20181$0.47$0.47$0.47
Q3 20181$0.44$0.44$0.44
Q4 20181$0.50$0.50$0.50
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Anika Therapeutics (NASDAQ:ANIK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Anika Therapeutics (NASDAQ:ANIK)
Insider Ownership Percentage: 6.57%
Institutional Ownership Percentage: 84.32%
Insider Trades by Quarter for Anika Therapeutics (NASDAQ:ANIK)
Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)
Insider Trades by Quarter for Anika Therapeutics (NASDAQ:ANIK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/16/2017Charles H SherwoodCEOSell3,293$60.04$197,711.72View SEC Filing  
10/13/2017Charles H SherwoodCEOSell7,124$60.08$428,009.92View SEC Filing  
7/27/2017Charles H SherwoodCEOSell63,799$50.79$3,240,351.21View SEC Filing  
7/5/2017Charles H SherwoodCEOSell14,201$50.03$710,476.03View SEC Filing  
5/22/2017Jeffery S ThompsonDirectorSell10,725$47.39$508,257.75View SEC Filing  
11/9/2016Joseph I BowerDirectorSell540$43.39$23,430.60View SEC Filing  
2/25/2016Raymond J LandDirectorSell2,695$43.62$117,555.90View SEC Filing  
2/27/2015Raymond J LandDirectorSell4,621$39.49$182,483.29View SEC Filing  
5/1/2014Charles H SherwoodCEOSell83,780$44.32$3,713,129.60View SEC Filing  
2/28/2014Charles H SherwoodCEOSell200,000$41.70$8,340,000.00View SEC Filing  
8/22/2013John C MoranDirectorSell5,000$24.35$121,750.00View SEC Filing  
8/8/2013Steve E WheelerDirectorSell26,984$23.61$637,092.24View SEC Filing  
8/7/2013Steve E WheelerDirectorSell11,016$27.01$297,542.16View SEC Filing  
8/6/2013Farmaceutici S.P.A. FidiaMajor ShareholderSell1,270,000$24.52$31,140,400.00View SEC Filing  
7/15/2013Charles H SherwoodCEOSell75,000$20.11$1,508,250.00View SEC Filing  
7/9/2013Charles H SherwoodCEOSell49,185$18.06$888,281.10View SEC Filing  
7/5/2013Charles H SherwoodCEOSell34,662$18.01$624,262.62View SEC Filing  
6/19/2013Charles H SherwoodCEOSell1,847$18.00$33,246.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Anika Therapeutics (NASDAQ:ANIK)
Latest Headlines for Anika Therapeutics (NASDAQ:ANIK)
Source:
Loading headlines, please wait.

Social

Chart

Anika Therapeutics (ANIK) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.